Quadria Capital Closes USD 1.07 Billion Fund III to Drive Asias Healthcare Transformation

Published: 28 May 2025

Author: Precedence Research

Share :

27 May 2025

Confidence from investors has enabled Quadria Capital, Asia’s top healthcare private equity firm, to close its third fund at USD 1.07 billion, much more than its expected USD 800 million target. This marks South and Southeast Asia’s largest healthcare venture fund. Converting the expected co-investments into capital, the firm raised its total investable funds to about USD 1.3 billion and grew in various fast-growing healthcare businesses across the area.

In a time of global financial uncertainty, the majority of investments for this new fund came from sovereign wealth funds, institutional investors, and family offices in North America, Europe, the Middle East, and India. About 40% of the fund’s capital has gone to Aragen Life Sciences, NephroPlus, and Maxivision, and investments in two Southeast Asian companies are almost complete. Additionally, Quadria wants its new fund to support innovative healthcare businesses that create positive results as well as profits in a fast-changing market.

Statement from Quadria Leaders

Abrar Mir, Co-Founder & Managing Partner, Quadria Capital

“Fund III’s close, amid one of the most demanding fundraising climates in recent memory, is a powerful validation of our strategy and our mission. It reflects deep global investor conviction in the transformational opportunity in Asian healthcare, where social impact and financial performance go hand in hand.”

Dr. Amit Varma, Co-Founder & Managing Partner, Quadria Capital

“We are entering a golden decade of healthcare transformation in Asia. With rising healthcare consumption, tech adoption, and affordability, we expect strong momentum in India and Southeast Asia, especially across diagnostics, single-specialty hospitals, and pharma services. Fund III allows us to lead this evolution.”

Laurent Jaffart, Head of Private Equity, Quadria Capital

While Laurent Jaffart wasn't mentioned in this release, a fitting addition to emphasizing his role could be: “Our continued success in deploying and returning capital highlights the strength of our operational approach and deep sector expertise. We’re building future-ready healthcare platforms with strong fundamentals and scalable impact.”